Glaxo gets U.K. OK for Revolade; Lilly targets Middle East; Bill would limit fees on orphan drugs;

@FiercePharma: Novartis acknowledges investigation of allegations of sales scheme in India, some employees have been fired. Story | Follow @FiercePharma

@EricPFierce: ANSM in France says no problems found in Teva packaging of Furosemide product tampering a possibility. More | Follow @EricPFierce

@CarlyHFierce: Teva's at-risk launch of generic Protonix a bit riskier than it thought. Teva & Sun to pay $2.15B to Pfizer. Article | Follow @CarlyHFierce

> Walgreens has agreed to pay $80 million to settle allegations by U.S. authorities that it was a weak link in the supply chain for addictive drugs allowing millions of controlled substances, including oxycodone, to reach the black market. Story

> GlaxoSmithKline ($GSK) has finally won a green light from Britain's healthcare cost agency NICE for its platelet-boosting drug Revolade after it offered a discount. Report

> Eli Lilly ($LLY) has opened a regional headquarters in Dubai that will serve its efforts in Turkey, the Middle East, Africa, Russia and UAE. Story

> A new FDA warning letter accuses another Indian drugmaker, this time RPG Life Sciences, of playing loose with test results. Letter

> Drugmakers say China's much higher fees for imports compared to domestically produced drugs is keeping generics out of the market. Story

> A bill in the U.S. Senate that would give the FDA more control over large compounding pharmacies is nearing a vote. Story

Medical Device News

@FierceMedDev: Study: Balloon implant reduced rectal damage during prostate cancer treatment. Item | Follow @FierceMedDev

@DamianFierce: Diagnostics companies gouged Medicare by almost $1B in 2011, according to the feds. Report | Follow @DamianFierce

@MarkHFierce: We need your FMD Fierce 15 nominations. Submit them courtesy of this handy link: Nomination form | Follow @MarkHFierce

> RTI will drop $130M on Pioneer with eye on bone implants. News

> Mystery solved? Research blames ruptured plaque for stent related blood clots. More

> St. Jude wins FDA nods for low-friction cardiac devices. Article

Biotech News

@FierceBiotech: Firm tries startup's tech tricks for clinical trial recruitment. Article | Follow @FierceBiotech

 @JohnCFierce: Report stirs debate over the true impact of the genomics revolution. More | Follow @JohnCFierce

@RyanMFierce: Add this AMG386 data to VTec results, and Amgen is 2 for 2 with Ph3 oncology programs this year. Devil's in the details, though. | Follow @RyanMFierce

 @EmilyMFierce: At a genomics briefing on the Hill. NIH Director Francis Collins says 25,000 jobs in biomedical research will be lost due to sequestration. | Follow @EmilyMFierce

> Celgene bolsters case for closely watched arthritis drug with Ph3 data. Story

> Amgen notches positive PhIII results for top cancer drug. Report

> Amgen's big Asian push triggers $75M heart drug pact for Japan. News

Drug Delivery News

@MichaelGFierce: Pearl's porous particle platform nets $1.15B AstraZeneca buyout. More | Follow @MichaelGFierce

> Ocular draws funding from Baxter to support hydrogel delivery platform. Item

> Origami inspires 3-D folded structures for drug delivery. Article

> New research further reveals nano-gold's delivery potential, safety risk. Story

Biomarkers News

> Heart experts link biomarkers with high risk of 'silent strokes.' Report

> Stunted telomeres might flag breast cancer risk. Article

> Genetic biomarker could help scientists select cell lines for stem cell studies. More

> Cancer Research UK, Abcodia to develop blood Dx attuned to early-stage cancers. Item

> Biomarker aids in gestational diabetes risk prediction. Story

And Finally... A bill introduced by in the U.S. House would make it clear that developers of orphan drugs would not have to pay certain fees to fund the nation's health plan, but it would also put checks on drugmakers from taking a blockbuster and getting a big tax cut. Story

Suggested Articles

After years of having first-line liver cancer market to itself, Bayer’s Nexavar is getting major competition from Roche's Tecentriq.

Most of the recent enthusiasm around AbbVie’s new drugs has centered on Skyrizi and Rinvoq, but elagolix wants a piece of the spotlight, too.

During David Loew's tenure, Sanofi Pasteur bought Protein Sciences, whose recombinant technology is being applied to a COVID-19 vaccine.